Alerta

ANTIGEN BINDING MOLECULES AND METHODS OF USE

Resumen de: AU2024233069A1

The present disclosure describes antigen binding molecules, including antibodies, that specifically bind to the anti-CD20 scFv-14 or Gibbon ape leukemia virus gp70 protein, as well as molecules comprising the described sequences and cells presenting such molecules. The antigen binding molecules may be used in research, diagnostic, clinical, and other applications.

Methods of administering chimeric antigen receptor immunotherapy

Resumen de: AU2025220739A1

The disclosure provides cells comprising CD19-directed chimeric antigen receptor (CAR) genetically modified autologous T cell immunotherapy for the treatment of, e.g., relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Some aspects of the disclosure relate to methods of treatment and monitoring following infusion of T cell therapy provided herein. The disclosure provides cells comprising CD19-directed chimeric antigen receptor (CAR) genetically modified autologous T cell immunotherapy for the treatment of, e.g., relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Some aspects of the disclosure relate to methods of treatment and monitoring following infusion of T cell therapy provided herein. ug h e d i s c l o s u r e p r o v i d e s c e l l s c o m p r i s i n g - d i r e c t e d c h i m e r i c a n t i g e n r e c e p t o r ( ) u g g e n e t i c a l l y m o d i f i e d a u t o l o g o u s c e l l i m m u n o t h e r a p y f o r t h e t r e a t m e n t o f , e g , r e l a p s e d o r r e f r a c t o r y l a r g e - c e l l l y m p

NITROGEN-CONTAINING ANALOGS OF SALINOMYCIN FOR USE IN MULTIPLE MYELOMA (MM)

Resumen de: US2025281449A1

The invention relates compound of formula (I), enantiomers, mixture of enantiomers, diastereoisomers and mixture of diastereoisomers thereof:wherein W, X, Y and Z are as defined, for use in the treatment of Multiple Myeloma (MM). A pharmaceutical composition including a pharmaceutical acceptable vehicle and at least a compound of formula (I) is also included.

NEW DRUG APPLICATION

Resumen de: US2025281502A1

A method is disclosed for treating an individual afflicted by a multiple myeloma by a composition comprising at least one G-quadruplex (G4) stabilizer. Also disclosed is a composition comprising at least one G-quadruplex (G4) stabilizer for its use in a method for treating an individual afflicted by a multiple myeloma.

METHODS FOR TREATING CANCER USING COMBINATIONS OF EPIGENETIC THERAPIES AND RADIOCONJUGATE TARGETING AGENTS

Resumen de: US2025281654A1

The invention provides methods for treating a cancer, such as acute myeloid leukemia, in a mammalian subject that include administering to the subject (i) an epigenetic drug such as one or both an HDAC inhibitor and an LSD1/KDM1A inhibitor, and (ii) a radioisotope-labeled agent that targets cancer cells in the subject, wherein the amounts of the epigenetic drug(s) and radiolabeled agent, when administered in conjunction with one another, are therapeutically effective.

COMPOUNDS FOR TREATING MYELOID DISEASES WITH CHROMOSOMAL ABNORMALITIES

Resumen de: AU2024225818A1

The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, for use in the treatment of myeloid disorders, such as acute myeloid leukemia (AML), in subjects having at least one chromosome abnormality of 3q21 and/or 3q26.

METHODS OF TREATING NON-HODGKIN LYMPHOMA

Resumen de: AU2023373683A1

Methods of treating non-Hodgkin lymphoma by administering a multispecific antibody to a patient in need are provided. Methods of making such antibodies, and compositions, including pharmaceutical compositions, comprising such antibodies, are also provided.

BCMA-TARGETED CAR-T CELL THERAPY OF MULTIPLE MYELOMA

Resumen de: MX2025005091A

A method for assessing responsiveness of a subject to a treatment comprising T cells expressing a bivalent BCMA-targeting chimeric antigen receptor (CAR), comprising administering to the subject the T cells, and assessing the responsiveness of the subject to the treatment based on time length the subject maintains minimal residual disease (MRD) negative status.

METHODS OF TREATING ACUTE LEUKEMIA

Resumen de: WO2024097758A1

Provided herein are methods of treating acute leukemia, such as acute myeloid leukemia (AML), in an individual, such as an individual having a mutation within the nucleophosmin 1 (NPM1) gene or a rearrangement within the lysineK-methyltransferase 2A (KMT2A) gene, wherein the methods comprise administering a menin inhibitor, ziftomenib, to the individual at a dose of 600 milligrams daily.

BCMA-TARGETED CAR-T CELL THERAPY FOR MULTIPLE MYELOMA

Resumen de: IE20230360A1

Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an epitope of BCMA are administered to the subject.

COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS

Resumen de: US2025276961A1

Provided herein are compounds, preferably compounds inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, compositions thereof, and methods of their preparation, and methods of inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, and methods for treating diseases wherein modulation of BCR-ABL1 activity prevents, inhibits, or ameliorates the pathology and/or symptomology of the disease.

COMBINATION THERAPY WITH VENETOCLAX AND ZOTATIFIN FOR THE TREATMENT OF CANCER

Resumen de: WO2025184298A1

The invention features methods of treating a subject having a cancer (e.g., leukemia (e.g., acute myeloid leukemia), solid tumor, breast cancer, lung cancer, colorectal cancer, or pancreatic cancer) by administering venetoclax or a pharmaceutically acceptable salt thereof in combination with zotatifin or a pharmaceutically acceptable salt thereof.

Methods of Assessing Smoldering Multiple Myeloma

Resumen de: US2025277271A1

Provided are improved methods for prognosing a clinical outcome in a subject or diagnosing the subject with high-risk or stable smoldering multiple myeloma (SMM), comprising determining a 3D telomeres organization signature of a test sample from the subject, the test sample comprising plasma cells, applying a classification model to the 3D telomeres organization signature to obtain an output classification that is indicative of the clinical outcome or diagnosis of the subject. The classification model is trained to distinguish between stable SMM and high-risk SMM and consists of the telomere parameters: a) nuclear telomere distribution, a/c ratio, and total telomere length; b) a/c ratio and telomere numbers; c) a/c ratio and nuclear telomere distribution, or d) a/c ratio and telomere aggregates. Also provided are methods for treating a subject with high-risk or stable SMM.

NOVEL CAR T-CELL PRODUCT AND METHOD OF PREPARATION THEREOF

Resumen de: US2025276012A1

The present invention provides engineering of T cells to express a Chimeric Antigen Receptor (CAR), and compositions comprising the same. The present invention related to novel CD19-targeting CAR T cell product comprising second and third generation CAR gene for treating B-cell disorders including leukaemia and lymphoma. The present invention is also related to process of preparing the novel CAR T cell products.

COMPOSITIONS AND METHODS RELATED TO MULTIPLE MYELOMA-ASSOCIATED LONG NONCODING RNAS

Resumen de: US2025277213A1

Among the various aspects of the present disclosure are provisions of compositions and methods related to multiple myeloma-associated long noncoding RNAs. The present disclosure describes a composition that comprises a long non-coding RNA (lncRNA) inhibitor targeting LINC01432. Also disclosed is a method to select a treatment for a multiple myeloma patient, as well as to treat a multiple myeloma patient, both related to targeting LINC01432.

THERAPEUTIC COMBINATIONS COMPRISING A MULTI-SPECIFIC T CELL ENGAGER

Resumen de: WO2025181039A1

The invention relates to combination and combination therapies, particularly for the treatment of a myeloid malignancy, such as acute myeloid leukemia (AML) or a myelodysplastic syndrome (MDS). The combination therapies include (i) a recombinant binding protein comprising (a) an ankyrin repeat domain specifically binding CD3 and (b) at least one, at least two, or at least three further ankyrin repeat domains, wherein each of the at least one, at least two, or at least three further ankyrin repeat domains specifically binds one tumor-associated antigen, suitably one selected from the group consisting of CD123, CD33 and CD70, and (ii) a Bcl-2 inhibitor, e.g., venetoclax, or a pharmaceutically acceptable salt thereof and/or (iii) a hypomethylating agent, e.g., azacitidine or decitabine.

Methods of managing tumor flare in adoptive immunotherapy

Resumen de: AU2025217309A1

Provided herein are methods of treating a solid malignant tumor using antigen-specific T cells and methods of managing tumor flare in treatment of a solid malignant tumor using antigen-specific T cells. The methods provided herein improve the safety of treatment by informing the patient about the potential risks for tumor flare, telling the patient to contact his or her physician if tumor swelling occurs, counseling a patient with Waldeyer’s ring lymphadenopathy to contact his or her physician if shortness of breath or stridor occurs, or grading and managing tumor flare developed in the patient. Provided herein are methods of treating a solid malignant tumor using antigen-specific T cells and methods of managing tumor flare in treatment of a solid malignant tumor using antigen-specific T cells. The methods provided herein improve the safety of treatment by informing the patient about the potential risks for tumor flare, telling the patient to contact his or her physician if tumor swelling occurs, counseling a patient with Waldeyer's ring lymphadenopathy to contact his or her physician if shortness of breath or stridor occurs, or grading and managing tumor flare developed in the patient. ug u g r o v i d e d h e r e i n a r e m e t h o d s o f t r e a t i n g a s o l i d m a l i g n a n t t u m o r u s i n g a n t i g e n - s p e c i f i c c e l l s a n d m e t h o d s o f m a n a g i n g t u m o r f l a r e i n t r e a t m e n t o f a s o l i d m a l i g n a n t t u m o r u

ANTIGEN BINDING MOLECULES AND METHODS THEREOF I

Resumen de: US2025277060A1

The invention relates to antigen-binding molecules that specifically bind to IgM μ-chain antigen. In one embodiment, the antigen-binding molecule is an antibody that specifically binds to canine IgM μ-chain antigen. Chimeric molecules of the antibody conjugated to another heterologous moiety are also provided. In one embodiment, the heterologous moiety is monomethyl auristatin E (MMAE). A method of inhibiting cancer using the antibody or the chimeric molecule thereof is also provided. In another embodiment, the antibody-MMAE conjugate suppresses tumour development in a murine model of B cell lymphoma.

MODULATORS OF BCL6 PROTEOLYSIS AND ASSOCIATED METHODS OF USE

Resumen de: WO2025184594A1

This application pertains to the use of Compound (A): or a pharmaceutically acceptable salt thereof, for the treatment of various diseases or disorders, including, for example, advanced non-Hodgkin lymphoma (NHL), relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL), transformed follicular lymphoma, nodal T-follicular helper cell lymphoma (nTFHL), relapsed/refractory (R/R) nodal T-follicular helper cell lymphoma, nodal T-follicular helper cell lymphoma - angioimmunoblastic type (nTFHL- Al) / advanced angioimmunoblastic T-cell lymphoma (AITL), or relapsed/refractory (R/R) nodal T-follicular helper cell lymphoma - angioimmunoblastic type (nTFHL-AI) / angioimmunoblastic T-cell lymphoma (AITL).

CONJUGATED ANTIBODY OR BISPECIFIC T-CELL ENGAGER WHICH SELECTIVELY BINDS EITHER TCR BETA CONSTANT REGION 1 (TRBC1) OR TRBC2

Resumen de: EP4610654A2

The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.

THERAPEUTIC AND DIAGNOSTIC METHODS FOR MULTIPLE MYELOMA

Resumen de: CN120112796A

The present invention provides methods of administration directed to the treatment of cancer, such as multiple myeloma, with an anti-crystallizable fragment receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibody.

METHODS AND MEANS FOR DIAGNOSING AND RISK STRATIFICATION OF JUVENILE MYELOMONOCYTIC LEUKEMIA

Resumen de: CN120153256A

The present invention relates to the diagnosis and assessment of juvenile granulocytic leukemia (JMML). In particular, it relates to a method of diagnosing JMML in a subject, said method comprising: a) determining the amount of at least one biomarker present on or in hematopoietic stem and progenitor cells (HSPC) in a biological sample, said at least one biomarker being selected from the group consisting of i) Group I consisting of CD52, RAMP1, LTB, LST1, JAML, IFITM3, CD7, CD69, CD164, CD74, TNF, TFPI, DLK1, CD82, IGHM, CALCRL, RALA, SLC2A5, HSPA5, HLA-DRA, RABI1A, SELL, VAMPS, FCMR, CLEC7A, NDFIP1, CLEC9A, HCST, b) comparing the quantity determined in step a) with a reference; and c) diagnosing the JMML based on the comparison of step b). In addition, the invention also relates to a method for classifying subjects suffering from JMML as a low-risk or high-risk group of JMML. Furthermore, the invention relates to the use of at least one biomarker present on or in HSPC in a biological sample for diagnosing JMML in a subject suffering from or at risk of developing into JMML as a low-risk or high-risk group of JMML. Furthermore, the present invention relates to a kit for diagnosing JMML in a subject or classifying a subject suffering from JMML as a low-risk group or a high-risk group of JMML. Furthermore, the present invention relates to the use of an inhibitor for the treatment and/or prevention of JMML, said inhibitor specifically inhibiting at least one biomarker selected fr

Treatment of cd20-positive b-cell lymphoma with obituzumab

Resumen de: AU2025205481A1

The present invention relates to administration speed of obinutuzumab. The present invention relates to administration speed of obinutuzumab. ul u l h e p r e s e n t i n v e n t i o n r e l a t e s t o a d m i n i s t r a t i o n s p e e d o f o b i n u t u z u m a b

Methods of treating myelodysplastic syndrome and monitoring the treatment

Resumen de: TW202440945A

Methods of monitoring therapeutic efficacy in a subject with myelodysplastic syndrome (MDS) are provided. Also provided is a method of identifying a subject with MDS for treatment with a telomerase inhibitor, and methods of treating MDS. The methods include administering to the subject a telomerase inhibitor and assessing variant allele frequency (VAF) for one or more of the following genes: SF3B1, TET2, DNMT3A, ASXL1, and CUX1 in a biological sample obtained from the subject after administration of the telomerase inhibitor. In some cases, a 25% or more reduction in VAF identifies a subject who has an increased likelihood of benefiting from treatment with a telomerase inhibitor. In some instances, the telomerase inhibitor is imetelstat or imetelstat sodium.

Antibodies against cd38 for treatment of multiple myeloma

Nº publicación: IL322052A 01/09/2025

Solicitante:

GENMAB AS
GENMAB A/S

Resumen de: CN119119271A

Isolated human monoclonal antibodies and related antibody-based compositions and molecules that bind to human CD38 are described. Pharmaceutical compositions comprising the human antibodies and therapeutic and diagnostic methods of using the human antibodies are also described.